Skip to main content
OpenTrials
Completed

NCT Number: NCT01188200

Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes

The purpose of this study is to demonstrate the efficacy of a nutritional formula in patients with type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kuban State Medical University, Krasnodar, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has type 2 diabetes.
  • Subject is over 18 years of age.
  • Subject is a male, or a non-pregnant, non-lactating female.
  • Subject's BMI is > 20 kg/m2 and < 40 kg/m2.
  • Subject's HbA1c level is 6.5 - 11%.
  • If on a chronic thyroid medication or hormone replacement therapy, subject has been on constant dosage for at least two months prior to Screening Visit.
  • Subject's weight is stable for the past two months prior to Screening Visit.

Exclusion criteria

  • Subject uses exogenous insulin, Byetta or alpha-glucosidase inhibitor for glucose control.
  • Subject has type 1 diabetes.
  • Subject has history of diabetic ketoacidosis.
  • Subject has the following: current infection ; has had inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or antibiotics in the last 3 weeks prior to screening.
  • Subject has an active malignancy.
  • Subject has had significant cardiovascular event <6 months prior to study entry or history of congestive heart failure.
  • Subject has end stage organ failure.
  • Subject has history of severe gastroparesis, renal or hepatic disease.
  • Subject has an active metabolic, hepatic, or gastrointestinal disease or condition that may interfere with nutrient absorption, distribution, metabolism, or excretion, excluding diabetes.
  • Subject has a chronic, contagious, infectious disease.
  • Taking daily medications at doses that would interfere with nutrient absorption, metabolism, excretion, gastric motility, or blood glucose.
  • Subject has fainted or experienced other adverse event in response to blood collection prior to enrollment into this study.
  • Clotting or bleeding disorders.
  • Allergic or intolerant to any ingredient found in the test meal.

Treatment and study plan

Experimental nutritional formula #M979

Other

One two hundred and forty mL serving at test time, taken orally

Standard food

Other

Standard meal prior to test time

Primary outcomes

  1. The primary variable is glucose concentration

    Time frame: 0 to 240 minutes

Secondary outcomes

  1. Additional measures of glucose concentration

    Time frame: 0 to 240 mins

Sponsors and collaborators

Lead sponsor

Abbott Nutrition

Industry

Registry information

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Aug 25, 2010
Registry last updated
Aug 25, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.